Review articlePublished 2013

Acute myeloid leukaemia - therapy - past, present and future

Authors: Paul Faduola, Alan Hakim, Juli Mansnerus, Atsuko Imai, Rob O Neill

Translational Biomedicine

Volume 4 · Issue 2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Acute myeloid leukemia (AML) is characterized by genetic aberrations and a variable response to therapy which has made treatment of AML challenging. The objective of this paper is to review conventional treatments and their development, phase I-III clinical trials of new agents, novel pathways where future interventions may have therapeutic potential, and clinical trial assessment in AML. This study showed that a detailed understanding of the molecular changes associated with chromosomal and genetic abnormalities is necessary to pilot new therapy design. Although several deregulated proteins and genes have been identified, their diversity among AML patients have made it difficult to identify a single substance that can hit these diverse targets . New agents have shown promise but there remains a huge need to be met for effective and targeted therapies to be successful.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalTranslational Biomedicine
  • SubjectHaematology
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Paul Faduola”
  • BylineArticles whose byline prints “Alan Hakim”
  • BylineArticles whose byline prints “Juli Mansnerus”
  • BylineArticles whose byline prints “Atsuko Imai”
  • BylineArticles whose byline prints “Rob O Neill”